DAX24.621 +1,3%Est505.895 +0,8%MSCI World4.343 -0,1%Top 10 Crypto9,8000 -1,1%Nas26.091 -0,5%Bitcoin66.157 +0,2%Euro1,1617 -0,4%Öl110,2 +0,5%Gold4.539 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 SAP 716460 Infineon 623100 Siemens Energy ENER6Y Deutsche Telekom 555750 NEL ASA A0B733 Lufthansa 823212 Microsoft 870747 Micron Technology 869020 Allianz 840400 RENK RENK73 Alphabet A (ex Google) A14Y6F Amazon 906866 Münchener Rückversicherungs-Gesellschaft 843002
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Hoffnungsschimmer im Nahost-Konflikt: DAX deutlich höher -- Asiens Börsen uneinheitlich -- OHB: Neue Verteidigungsallianz -- POET, Kongsberg, Rheinmetall, RENK, Micron, AIXTRON, Gerresheimer im Fokus
Top News
Höhere Kosten: HORNBACH Holding setzt sich vorsichtige Ziele - Aktie dreht ins Minus Höhere Kosten: HORNBACH Holding setzt sich vorsichtige Ziele - Aktie dreht ins Minus
Japans Wirtschaftswachstum beschleunigt sich überraschend stark Japans Wirtschaftswachstum beschleunigt sich überraschend stark
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ipsen Aktie

Kaufen
Verkaufen
Ipsen Aktien-Sparplan
157,30 EUR +2,50 EUR +1,62 %
STU
144,04 CHF +2,96 CHF +2,10 %
BRX
finanzen.net zero
Ipsen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.13,73 Mrd. EUR

KGV22,18Div. Rendite1,34%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0ESMG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0010259150

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIPSEF

Ipsen Aktien News

DatumMeistgelesen
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024
GlobeNewswireIpsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
GlobeNewswireIpsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
GlobeNewswireIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
GlobeNewswireIpsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
GlobeNewswireIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
GlobeNewswireIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
GlobeNewswireIpsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
GlobeNewswireHalf-year statement of IPSEN liquidity agreement - 2024 06 30
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
GlobeNewswireIpsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
GlobeNewswireIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
GlobeNewswireIpsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswireIpsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    
GlobeNewswireIpsen initiates a share buy-back program to cover its free employee share-allocation plan
GlobeNewswireIpsen announces the launch of an employee shareholding plan
GlobeNewswireAnnual General Meeting of Ipsen S.A. held on 28 May 2024
GlobeNewswireDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
GlobeNewswireIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Keira Driansky as EVP, President of North America
GlobeNewswireIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PR NewswireIpsen und Skyhawk Therapeutics geben Zusammenarbeit bei der Erforschung seltener neurologischer Erkrankungen durch RNA-Targeting bekannt
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
GlobeNewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
GlobeNewswireIpsen publishes its 2023 Universal Registration Document
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
PR NewswireMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
GlobeNewswireIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.